A case of treatment of cervical adenocarcinoma associated with pregnancy by zinc-citrate compound (SeLava(R)).

Choi, Ji Hyang; Lee, Yong Seok; Jung, Chan Kwon; Park, Lae Ok; Bae, Seog Nyeon

Case Report

Korean Journal of Obstetrics & Gynecology 2006;49(12):2612-2619.
Published online December 1, 2006.

A case of treatment of cervical adenocarcinoma associated with pregnancy by zinc-citrate compound (SeLava(R)).

Ji Hyang Choi, Yong Seok Lee, Chan Kwon Jung, Lae Ok Park, Seog Nyeon Bae

¹Department of Obstetrics and Gynecology, Kangnam St. Mary's Hospital, The Catholic University of Korea. seognbae@catholic.ac.kr
²Department of Hospital Pathology, Kangnam St. Mary's Hospital, The Catholic University of Korea.

Abstract

Cervical carcinoma is the second leading cause of death from cancer in women worldwide. It is well known that human papillomaviruses (HPVs) is the etiologic agent of cervical neoplasia and cervical cancer. Zinc has been shown to inhibit the growth of malignant cell lines by inducing apoptosis and cell cycle arrest. Recently it was reported that zinc-citrate compound (CIZAR(R)) has a cytotoxic effect on choriocarcinoma cell line and ovarian adenocarcinoma cell line and suppresses its proliferation inducing apoptosis. CIZAR(R) prevents the proliferation by inactivation of m-aconitase activity and induces apoptosis by increasing Bax expression and reducing Bcl-2 expression and inactivation of telomerase. We report one patient of cervical adenocarcinoma with HPV infection, who desires to continue pregnancy, treated by daily topical application of SeLava(R) which contains zinc-citrate compound (CIZAR(R)). We followed up the cytologic, pathologic and coloposcopic changes of healing process.

Key Words: Cervical adenocarcinoma, Pregnancy, Zinc-citrate compound